Edition:
India

Mediwound Ltd (MDWD.OQ)

MDWD.OQ on NASDAQ Stock Exchange Global Market

4.80USD
15 Dec 2017
Change (% chg)

$0.10 (+2.13%)
Prev Close
$4.70
Open
$4.65
Day's High
$4.80
Day's Low
$4.60
Volume
25,148
Avg. Vol
9,993
52-wk High
$8.25
52-wk Low
$4.20

Summary

Name Age Since Current Position

Stephen Wills

59 2017 Chairman of the Board

Cal Cohen

2006 Chief Executive Officer

Sharon Malka

2007 Chief Financial Officer

Eilon Asculai

2007 Vice President, Research & Development

Lior Rosenberg

Chief Medical Officer

Vickie Driver

2017 Director

Biographies

Name Description

Stephen Wills

Mr. Stephen T. Wills, CPA., is Chairman of the Board of the Company. He has served, since 1997, as Executive Vice President, Secretary, Treasurer and Chief Financial Officer of Palatin Technologies, Inc., a publicly-held biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential. He has served in various roles in Palatin since 1997, including as Executive Vice President of Operations from 2005 until June 2011 and as Chief Operating Officer and Executive Vice President from 2011 to present. Mr. Wills served as Executive Chairman and Interim Principal Executive Officer of Derma Sciences, Inc., a publicly-held company providing advanced wound care products, from December 2015 until February 2017 when Derma was acquired by Integra LifeSciences Holding Corporation. Mr. Wills also served as the lead director of Derma Sciences until December 2015 and as Derma Science's Chief Financial Officer from 1997 to 2000. Mr. Wills serves on the board of trustees and executive committee of The Hun School of Princeton, and from 1991 to 2000 he was the President and Chief Operating Officer of Golomb, Wills & Company, P.C., a public accounting firm. Mr. Wills, a certified public accountant, received his B.S. in accounting from West Chester University, and an M.S. in taxation from Temple University.

Cal Cohen

Mr. Gal Cohen had been serving as Chief Executive Officer of Mediwound, Ltd since November 2006. Prior to joining the Company, Mr. Cohen held several management positions at Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) as Director of Strategic Business Planning and New Ventures, Projects Manager for the Global Products Division and Team Leader at Teva's Corporate Industrial engineering department. During this period, he led various business transactions and alliances with start-up companies and academic institutions, was the Project Manager of the launch of Copaxone, Teva's product, in numerous countries as well as developed various medical devices. Mr. Cohen holds a cum laude Bachelor of Science in Industrial Engineering and Management from the Technion-Israel's Institute of Technology, and a cum laude Master of Business Administration from Tel-Aviv University.

Sharon Malka

Mr. Sharon Malka serves as Chief Financial Officer at MediWound Ltd since April 2007. Prior to joining the Company, he served as a partner at Varinace Economic Consulting Ltd., a full-service consulting firm and as a senior manager at Kesselman Corporate Finance, a division of PricewaterhouseCoopersGlobal Network (PwC). Mr. Malka's experience includes business and economic consulting for a number of public companies regarding valuations, SEC filing, feasibility studies and financial/strategic planning. Mr. Malka holds a Bachelor of Science in Business Administration from the Business ManagementCollege, Israel and an MBA from Bar Ilan University, Israel.

Eilon Asculai

Dr. Eilon Asculai serves as Vice President, Research and Development at MediWound Ltd. since July 2007. Prior to joining the Company, he was the Senior Director of the Pharmaceutical R&D at Perrigo Israel Pharmaceuticals. In this position he managed all pharmaceutical development activities from initiation to submission. He led a considerable senior scientific and technical staff in the process of development of generic and innovative products. Prior to his last position, he served for nine years, in various management positions in Perrigo in Pharmaceutical R&D. He holds a Bachelor of Science, Master of Science (Summa cum Laude), doctorate of Philosophy in Medical Sciences, and Master of Business Administration (hons.) degrees, all from the Ben-Gurion University.

Lior Rosenberg

Prof. Lior Rosenberg serves as Chief Medical Officer of MediWound Ltd since its inception. He was one of the founders of the Company. He is also a memberof the Board of Directors of MediWound Ltd. He is the head of the Department of Plastic Surgery at Soroka University Medical Center in Beer Sheva, heads the unit for Cleft Lip Palate & Craniofacial deformities at Meir Medical Center,Kfar Saba, and is a Professor of Medicine at the Ben-Gurion University MedicalSchool in Beer Sheva. He holds a Master of Doctorate degree.

Vickie Driver

Dr. Vickie R. Driver is Director of the company. She is board certified in foot surgery by the American Board of Podiatric Surgery and is a Fellow at the American College of Foot and Ankle Surgeons, licensed in Rhode Island. Her career as a podiatric physician and surgeon has included a special emphasis on limb preservation and wound healing in her medical practice, as well as, research and education. Dr. Driver is a Professor of Surgery in the Department of Orthopedics at Brown University (Clinical). She has served for 9 years on the Board of Directors for the Association for the Advancement of Wound Care ("AAWC"), and recently completed her tenure as president for this international organization. Dr. Driver is also the chair of Wound Care Experts and U.S. Food and Drug Administration (FDA) Clinical Endpoints Project. She has just been named to serve as member at large to the Board of Directors of the Wound Healing Society (WHS) and Board Member to the Critical Limb Ischemia (CLI) Global Society. In addition, she serves on multiple clinical national and international committees that focus on preventing limb loss and improving wound healing in the high-risk population. She is considered an outspoken ambassador and patient advocate for lower extremity limb preservation and amputation prevention. She has served as an investigator for more than 70 important multi-center randomized clinical trials, as well as developed and supervised multiple research fellowship training programs. She has served and chaired multiple committees for large national and international pivotal clinical trials and has authored over 120 publications and abstracts. Dr. Driver is credited with the development and directorship of multiple major multidisciplinary Limb Preservation- Wound Healing Centers of Excellence, including Military/VA, Hospital and University based programs. She currently serves as Director, Translational Medicine, Wound Healing, Novartis Institute for Biomedical Research.

Basic Compensation

Options Compensation